Zoetis (ZTS) PT Raised to $101.00 at JPMorgan Chase & Co.

Zoetis (NYSE:ZTS) had its price objective boosted by JPMorgan Chase & Co. from $100.00 to $101.00 in a report issued on Friday. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald set a $98.00 price objective on shares of Zoetis and gave the stock a buy rating in a report on Thursday, August 2nd. Bank of America lifted their price objective on shares of Zoetis from $97.00 to $100.00 and gave the stock a buy rating in a report on Monday, July 30th. Jefferies Financial Group set a $96.00 price objective on shares of Zoetis and gave the stock a buy rating in a report on Friday, July 13th. Stifel Nicolaus lifted their price objective on shares of Zoetis from $86.00 to $95.00 and gave the stock a buy rating in a report on Friday, August 3rd. Finally, Argus lifted their price objective on shares of Zoetis from $90.00 to $103.00 and gave the stock a buy rating in a report on Tuesday, August 14th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $93.19.

NYSE ZTS opened at $92.72 on Friday. Zoetis has a 12-month low of $67.76 and a 12-month high of $96.57. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. The firm has a market capitalization of $44.70 billion, a P/E ratio of 38.63, a price-to-earnings-growth ratio of 1.74 and a beta of 0.97.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The business had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter last year, the firm posted $0.65 EPS. Zoetis’s revenue was up 9.9% compared to the same quarter last year. On average, sell-side analysts expect that Zoetis will post 3.1 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Tuesday, November 20th will be paid a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date is Monday, November 19th. Zoetis’s payout ratio is 20.83%.

In other news, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction on Monday, October 1st. The stock was sold at an average price of $92.03, for a total transaction of $184,060.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Glenn David sold 16,385 shares of Zoetis stock in a transaction on Monday, August 20th. The stock was sold at an average price of $92.20, for a total value of $1,510,697.00. Following the sale, the chief financial officer now owns 29,234 shares in the company, valued at $2,695,374.80. The disclosure for this sale can be found here. Insiders have sold a total of 200,201 shares of company stock worth $18,306,772 over the last quarter. Company insiders own 0.35% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Signature Estate & Investment Advisors LLC bought a new stake in shares of Zoetis during the 3rd quarter worth $112,000. Sun Life Financial INC raised its stake in Zoetis by 604.3% in the 2nd quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock valued at $112,000 after acquiring an additional 1,124 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its stake in Zoetis by 3,033.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock valued at $120,000 after acquiring an additional 1,365 shares during the period. Fort L.P. bought a new stake in Zoetis in the 2nd quarter valued at about $121,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Zoetis in the 3rd quarter valued at about $146,000. Institutional investors own 89.68% of the company’s stock.

Zoetis Company Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Read More: How a Put Option Works

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply